Chadi is delighted and honored to host an icon and pioneer in precision medicine and the molecular understanding of cancer as we know it: Ray Kurzrock, MD, FACP, Center Associate Director and Professor at the Medical College of Wisconsin as well as CMO of the WIN consortium.
Nobody knows the history of precision medicine like Ray does. She was doubted when she started, but her resilience and perseverance led to unprecedented progress that she led along with her mentors, mentees, and colleagues.
She details her early appointment to leading the phase I trials at MD Anderson Cancer Center and developing a protocol for matching targeted therapy trials to the right patients, the origins of the term “precision medicine,” resistance to precision medicine and genomics by different stakeholders, how accelerated approvals are better suited for precision medicine versus randomized controlled trials, and a host of other topics in this riveting and spirited dialogue.
We owe much of our current understanding of cancer as a molecularly driven disease to Ray as she had an immeasurable impact on the field.
N/A
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
